PMID- 26608378
OWN - NLM
STAT- MEDLINE
DCOM- 20160926
LR  - 20151207
IS  - 1573-8221 (Electronic)
IS  - 0007-4888 (Linking)
VI  - 160
IP  - 1
DP  - 2015 Nov
TI  - The Use of Release-Active Antibody-Based Preparations for Vertigo Prevention in 
      Adults.
PG  - 61-3
LID - 10.1007/s10517-015-3098-z [doi]
AB  - The effectiveness of antibody-based release-active preparations Impaza 
      (antibodies to eNOS), Tenoten (antibodies to brain-specific protein S-100), 
      Dietressa (antibodies to type 1 cannabinoid receptor), Brizantin (combined 
      preparation, antibodies to brain-specific protein S-100 and type 1 cannabinoid 
      receptor), and Divaza (combined preparation, antibodies to brain-specific protein 
      S-100 and eNOS) in the prevention of vertigo was studied on the model of 
      intermittent accumulation of Coriolis accelerations (ICCA). Modification of 
      activity of vestibular receptors and signal systems by release-active 
      preparations contributed to an increase in ICCA tolerance time. Combined 
      preparation Impaza possessed the most significant antinaupathic properties. 
      Brizantin was less potent in this respect.
FAU - Barchukov, V V
AU  - Barchukov VV
AD  - Materia Medica Holding, Moscow, Russia.
FAU - Zhavbert, E S
AU  - Zhavbert ES
AD  - Materia Medica Holding, Moscow, Russia. zhavbertes@materiamedica.ru.
FAU - Dugina, Yu L
AU  - Dugina YL
AD  - Materia Medica Holding, Moscow, Russia.
FAU - Epstein, O I
AU  - Epstein OI
AD  - Materia Medica Holding, Moscow, Russia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20151125
PL  - United States
TA  - Bull Exp Biol Med
JT  - Bulletin of experimental biology and medicine
JID - 0372557
RN  - 0 (Antibodies)
RN  - 0 (Brizantin)
RN  - 0 (CNR1 protein, human)
RN  - 0 (Dietressa)
RN  - 0 (Drug Combinations)
RN  - 0 (IMPAZA)
RN  - 0 (Receptor, Cannabinoid, CB1)
RN  - 0 (S100 Proteins)
RN  - 0 (divaza)
RN  - 0 (tenoten)
RN  - EC 1.14.13.39 (NOS3 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
SB  - IM
MH  - Acceleration/adverse effects
MH  - Adolescent
MH  - Adult
MH  - Antibodies/*therapeutic use
MH  - Coriolis Force
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nausea/etiology/physiopathology/prevention & control
MH  - Nitric Oxide Synthase Type III/immunology
MH  - Primary Dysautonomias/etiology/physiopathology/prevention & control
MH  - Receptor, Cannabinoid, CB1/immunology
MH  - S100 Proteins/immunology
MH  - Severity of Illness Index
MH  - Space Motion Sickness/etiology/physiopathology/*prevention & control
MH  - Vestibule, Labyrinth/drug effects
MH  - Young Adult
OTO - NOTNLM
OT  - Brizantin
OT  - Divaza
OT  - release-active antibody-based preparations
OT  - vertigo
EDAT- 2015/11/27 06:00
MHDA- 2016/09/27 06:00
CRDT- 2015/11/27 06:00
PHST- 2014/05/27 00:00 [received]
PHST- 2015/11/27 06:00 [entrez]
PHST- 2015/11/27 06:00 [pubmed]
PHST- 2016/09/27 06:00 [medline]
AID - 10.1007/s10517-015-3098-z [pii]
AID - 10.1007/s10517-015-3098-z [doi]
PST - ppublish
SO  - Bull Exp Biol Med. 2015 Nov;160(1):61-3. doi: 10.1007/s10517-015-3098-z. Epub 
      2015 Nov 25.